SCHEMBL16635685

SCHEMBL16635685

O=C(O)C1CCCCC1c1nc(-c2ccc(F)cc2)oc1-c1ccc(N2CCS(=O)(=O)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSK P43235 7/20 0.54
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 2/20 0.37
S1PR1 P21453 1/20 0.37
FAAH O00519 5/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NOTUM Q6P988 1/20 0.35
TP53 P04637 2/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16635997 1.00 CTSK (0.54) CTSKL3MBTL1KDM4ES1PR1FAAH
SCHEMBL16635996 0.93 CTSK (0.47) CTSKL3MBTL1KDM4ES1PR1MEN1
SCHEMBL16635684 0.93 CTSK (0.47) CTSKL3MBTL1KDM4ES1PR1MEN1
SCHEMBL16636475 0.90 CTSK (0.54) CTSKL3MBTL1KDM4EFAAHMEN1
SCHEMBL16635711 0.84 CTSK (0.79) CTSK
SCHEMBL16636476 0.82 CTSK (0.47) CTSKL3MBTL1KDM4EMEN1KMT2A
SCHEMBL16635709 0.77 CTSK (0.70) CTSK
SCHEMBL16635941 0.76 CTSK (0.72) CTSK
SCHEMBL16635861 0.75 SMN1; SMN2 (0.38) CTSKKDM4ETP53ALDH1A1HPGD
SCHEMBL16617749 0.73 CTSK (0.55) CTSKKDM4EFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ CTSK 4/4885L3MBTL1 373/4885KDM4E 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.